UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2022

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

001-37471

(Commission

Nevada (State or other jurisdiction of

30-0784346

(IRS Employer

Incorporation)		File Number)		Identification No.)						
	29	55 State Street, 9th Floor	02109							
		Boston, MA								
	(Add	ress of principal executive offices)	(Zip Code)							
	Reg	istrant's telephone number, includi N/A	ng area code: 857-24	46-8998						
	(F	ormer name or former address, if c	hanged since last re	port.)						
	he appropriate box below if the Form 8 ng provisions:	-K filing is intended to simultaneously	y satisfy the filing ob	oligation of the registrant under any of the						
	Written communications pursuant to	Rule 425 under the Securities Act (17	CFR 230.425)							
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)									
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))									
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))										
ecuritie	es registered pursuant to Section 12(b) of the	e Act:								
Title of each class		Trading Symb	ool(s)	Name of each exchange on which registered						
	Common Stock, \$0.001 par value per share	PIRS		The Nasdaq Capital Market						
	by check mark whether the registrant b-2 of the Securities Exchange Act of b		fined in Rule 405 of	the Securities Act of 1933 (17 CFR §230.405) or						
mergii	ng Growth Company □									
	nerging growth company, indicate by ched financial accounting standards provi			ed transition period for complying with any new						

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 4, 2022, Pieris Pharmaceuticals, Inc. (together with its wholly-owned subsidiary, Pieris Pharmaceuticals GmbH, the "Company") announced that Tim Demuth, M.D., Ph.D. has mutually agreed with the Company to step down effective September 30, 2022 ("Separation Date"). Dr. Demuth had served as Pieris' Senior Vice President and Chief Medical Officer. Pursuant to the terms of the separation agreement entered into with Dr. Demuth on August 4, 2022 (the "Separation Agreement"), he will be entitled to receive continuation payments of his base salary for two months, payable over the 2-month period prior to his Separation Date, and the Company will continue to contribute to his retirement benefits until the Separation Date. In addition, Dr. Demuth will be entitled to receive a pro-rata share of his 2022 discretionary bonus, and severance payment in an amount of ϵ 265,125 (equivalent to \$270,427 based on an exchange rate of \$1.02 to ϵ 1.00).

Dr. Demuth's right to receive the foregoing is subject to, among other obligations, his execution of a release of claims against the Company, as well as certain ongoing confidentiality obligations. The foregoing is a summary description of the terms and conditions of the Separation Agreement and is qualified in its entirety by reference to the Separation Agreement, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

Cover Page Inte	eractive Data File (embed	dded within the Inline	e XBRL document).			

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

Dated: August 4, 2022 /s/ Tom Bures

Tom Bures

Chief Financial Officer